Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
2022 · Nature Medicine · 332 citations
https://doi.org/10.1038/s41591-022-01851-x
K
Karijn P.M. Suijkerbuijk
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
266
Papers
8.5K
Citations
36
h-index
103
i10-index
Karijn P.M. Suijkerbuijk is an academic researcher from Utrecht University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Cutaneous Melanoma Detection and Management & CAR-T cell therapy research. The author has an h-index of 36, co-authored 227 publications.
ORCID: 0000-0003-3604-5430Papers by this author
worksReceptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
2017 · JNCI Journal of the National Cancer Institute · 297 citations
https://doi.org/10.1093/jnci/djx273
The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2α
2007 · Oncogene · 128 citations
https://doi.org/10.1038/sj.onc.1210795
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
2023 · npj Precision Oncology · 100 citations
https://doi.org/10.1038/s41698-023-00380-1
Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study
2022 · European Journal of Cancer · 56 citations
https://doi.org/10.1016/j.ejca.2022.02.026
Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response
2020 · Cancers · 41 citations
https://doi.org/10.3390/cancers12082072
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat